RALEIGH, N.C., Jan. 9, 2014 /PRNewswire/ -- PRA, a leading clinical research organization, today announced it is a finalist in the category of Best Life Science Contract Research Organization of the Year for the 4th annual BioPharma Asia Industry Awards. Last year, PRA was voted "Best CRO" for the 3rd annual BioPharma Asia Industry Awards.
This year's winner will be determined by an online voting contest. Voting is currently open and closes Feb. 28. To vote, go to http://svy.mk/1fc9FK9. The winner will be announced March 11 at an awards dinner in Singapore.
"It is truly an honor to be nominated for the second year in a row," said PRA Executive Vice President, Scientific and Medical Affairs, Kent Thoelke. "We strive to provide high-quality services and have been strategically expanding our operations in the Asia Pacific region."
"The company is increasing project work in new territories as a result of its joint venture, WuXiPRA," said PRA Regional Director, Clinical Operations – Asia Pacific, Helen Neal. "PRA is expanding operations and expediting progress for clients in Asia Pacific by leveraging local expertise within global technology platforms." Neal added that regulatory expertise plays a vital role in guiding and supporting PRA's partners' decisions regarding the optimum pathway to product registration.
Organized by Terrapinn, a business media company, the awards honor and generate public recognition of the efforts, accomplishments and positive contributions of organizations and individuals in Asia's biopharmaceutical industry. There are eight award categories: Best LSP Award; Best Contract Research Organization Award; Best Contract Manufacturing Organization Award; Most Innovative Asian Biotech Award; Asian Executive of the Year; Woman Executive of the Year; Best Manufacturing Solution Provider Award; and Pharma Company of the Year.
One of the world's largest CROs, PRA is transforming clinical trials through our people, innovation and operational transparency. Our 10,000+ employees operate in more than 80 countries, delivering a broad spectrum of full-service and Embedded clinical trial solutions that meet the demands of a diverse marketplace.
Over the last 30+ years, PRA has established a reputation for specialized expertise and success in a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. Our forward-thinking approach to clinical research innovation, customized recruitment strategies and technological advances continues to make a difference to healthcare patients around the world.